Molecular Diagnostics Forms a Medical Advisory Board with Dr. George Gorodeski.CHICAGO -- Molecular Diagnostics, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : MCDG.OB) announces the formation of a Scientific Medical Advisory Board. The first individual to join that Board is Dr. George Gorodeski, MD, Ph.D. Dr. Gorodeski is a leader in women's reproductive health Within the framework of WHO's definition of health[1] as a state of complete physical, mental and social well-being, and not merely the absence of disease or infirmity, reproductive health, or sexual health/hygiene issues. He is the Professor of Reproductive Biology, Professor of Oncology, and Professor of Physiology and Biophysics biophysics, application of various methods and principles of physical science to the study of biological problems. In physiological biophysics physical mechanisms have been used to explain such biological processes as the transmission of nerve impulses, the muscle at Case Western Reserve University. Dr. Gorodeski has been lead investigator or co-investigator in over 40 different grant sponsored trials. Over the last 26 years, Dr. Gorodeski has had 90 papers published in different medical and scientific journals. For the past nine years, Dr. Gorodeski has been active with and currently serves as the acting President of the North American North American named after North America. North American blastomycosis see North American blastomycosis. North American cattle tick see boophilusannulatus. Menopause menopause (mĕn`əpôz) or climacteric (klīmăk`tərĭk, klī'măktĕr`ĭk) Society. Dr. Gorodeski is the co-inventor of Molecular's e2 Collector. Dr. George Gorodeski said "I was involved in the early years with the development of Molecular Diagnostic technology. I believe this Company has a portfolio of world class technology that is essential to addressing women's reproductive health issues. I am very pleased to see the changes that are occurring with Molecular Diagnostics and look forward to actively participating in the successful launch of these technologies. I see this company developing into an organization which can effectively grow new technologies, and anticipate being able to bring new opportunities to Molecular Diagnostics. As the co-inventor of the e2 Collector, I am especially interested in this product, and anticipate getting further collaborative testing done on the collector to demonstrate its superiority, and having a peer review article published. Dr. Weissberg, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , stated, "Dr. Gorodeski's participation on our newly formed Scientific Medical Advisory Board is very exciting to me. Dr. Gorodeski has a long and distinguished history of innovative and productive scientific work addressing women's health Women's Health Definition Women's health is the effect of gender on disease and health that encompasses a broad range of biological and psychosocial issues. issues. He represents the caliber of individuals that we intend to gather in support of Molecular's technology. For Dr. Gorodeski to warmly offer to participate on our Medical Advisory Board speaks volumes about the man and his commitment to the benefits of this technology getting into widespread commercial use. We are looking forward to rebuilding Molecular's close working relationship with Case Western Reserve University and their outstanding medical scientific team." About Molecular Diagnostics, Inc. Molecular Diagnostics develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, gastrointestinal, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with a highly accurate, low-cost, cervical cancer Cervical Cancer Definition Cervical cancer is a disease in which the cells of the cervix become abnormal and start to grow uncontrollably, forming tumors. screening system that can be integrated into existing medical models or at the point-of-care. More information is available at: www.Molecular-Dx.com Certain statements in this release are forward-looking. These statements are based on Molecular Diagnostics' current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate To establish the existence or truth of a particular fact through the use of competent evidence; to verify. For example, an Eyewitness might be called by a party to a lawsuit to substantiate that party's testimony. Molecular Diagnostics' expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by Molecular Diagnostics with the Securities and Exchange Commission. Actual results may differ materially from Molecular Diagnostic's current expectations depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2004 and its Quarterly Reports on Form 10-QSB for the quarters ended March 31, 2005 and June 30, 2005. Except as expressly required by law, Molecular Diagnostics undertakes no obligation to publicly update or revise any forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. contained herein. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion